Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amylyx Pharmaceuticals Inc ( (AMLX) ) has provided an update.
On September 9, 2025, Amylyx Pharmaceuticals, Inc. announced an underwriting agreement to issue and sell 17,500,000 shares of its common stock at $10.00 per share, potentially raising approximately $164.0 million. The proceeds are intended for advancing avexitide commercial readiness, research and development, and general corporate purposes, with the offering expected to close on September 11, 2025.
The most recent analyst rating on (AMLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.
Spark’s Take on AMLX Stock
According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.
Amylyx Pharmaceuticals’ overall stock score is primarily impacted by its financial performance challenges, including declining revenues and operational losses. While technical analysis shows positive momentum, the company’s valuation is weak due to a negative P/E ratio and lack of dividends. The recent halt of the ORION program further adds to the uncertainty, despite some positive developments in other clinical trials.
To see Spark’s full report on AMLX stock, click here.
More about Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurodegenerative diseases. The company is advancing its product, avexitide, towards commercial readiness.
Average Trading Volume: 1,583,665
Technical Sentiment Signal: Buy
Current Market Cap: $930.9M
See more data about AMLX stock on TipRanks’ Stock Analysis page.